STOCK TITAN
  1. Home
  2. Sec-filings
  3. IDXG
  4. [8-K] INTERPACE BIOSCIENCES, INC. Reports Material Event

Interpace Biosciences (IDXG) sees all 2026 meeting items pass

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

INTERPACE BIOSCIENCES, INC. (IDXG) reported the results of its 2026 annual meeting of stockholders held on August 20, 2026. Stockholders approved all matters submitted to a vote, including the election of directors and several additional proposals.

Directors Vijay Aggarwal, Thomas W. Burnell, Joseph D. Keegan, Ph.D., Fortunato Ron Rocca, and Stephen J. Sullivan each received over 24.4 million votes in favor, with no votes against and between 135,575 and 808,652 votes withheld, plus 1,347,136 broker non-votes for each nominee.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Vijay Aggarwal 25,093,904 Votes for director election at 2026 annual meeting, with 137,454 withheld and 1,347,136 broker non-votes
Votes for Thomas W. Burnell 25,095,783 Votes for director election at 2026 annual meeting, with 135,575 withheld and 1,347,136 broker non-votes
Votes for Joseph D. Keegan, Ph.D. 24,422,783 Votes for director election at 2026 annual meeting, with 808,575 withheld and 1,347,136 broker non-votes
Votes for Fortunato Ron Rocca 24,422,706 Votes for director election at 2026 annual meeting, with 808,652 withheld and 1,347,136 broker non-votes
Votes for Stephen J. Sullivan 24,422,713 Votes for director election at 2026 annual meeting, with 808,645 withheld and 1,347,136 broker non-votes
Representative proposal vote total (For) 26,442,760 For votes on one of the approved proposals at the 2026 annual meeting, with 134,660 against and 1,074 abstain
Annual meeting date August 20, 2026 Date of the 2026 annual meeting of stockholders
Broker Non-Vote financial
"For | Against | Abstain | Broker Non-Vote"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Submission of Matters to a Vote of Security Holders regulatory
"Item 5.07. Submission of Matters to a Vote of Security Holders."

FAQ

What did INTERPACE BIOSCIENCES (IDXG) announce regarding its 2026 annual meeting?
INTERPACE BIOSCIENCES, INC. reported that its 2026 annual meeting of stockholders was held on August 20, 2026 and that stockholders approved all matters submitted to a vote, including the election of directors and several additional proposals.

Were the director nominees elected at INTERPACE BIOSCIENCES (IDXG)’s 2026 annual meeting?
Yes. Director nominees Vijay Aggarwal, Thomas W. Burnell, Joseph D. Keegan, Ph.D., Fortunato Ron Rocca, and Stephen J. Sullivan were each elected, receiving over 24.4 million votes in favor and 0 votes against, with some votes withheld and broker non-votes.

How many votes did Vijay Aggarwal receive at INTERPACE BIOSCIENCES (IDXG)’s 2026 meeting?
Vijay Aggarwal received 25,093,904 votes for election, 0 votes against, 137,454 votes withheld, and there were 1,347,136 broker non-votes in connection with his election as a director.

How many votes did Thomas W. Burnell receive for election as a director of INTERPACE BIOSCIENCES (IDXG)?
Thomas W. Burnell received 25,095,783 votes for election, 0 votes against, 135,575 votes withheld, and there were 1,347,136 broker non-votes in connection with his election as a director.

Did INTERPACE BIOSCIENCES (IDXG) report any broker non-votes at the 2026 annual meeting?
Yes. For the director elections, there were 1,347,136 broker non-votes reported for each of the five nominees. Several other proposals also show 1,347,136 broker non-votes in their respective vote tallies.

Who signed the INTERPACE BIOSCIENCES (IDXG) report on the 2026 annual meeting results?
The report on the 2026 annual meeting voting results was signed on behalf of INTERPACE BIOSCIENCES, INC. by Thomas W. Burnell, who is identified as the company’s President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001054102 0001054102 2026-08-20 2026-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) August 20, 2026

 

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

DELAWARE  

000-24249

   22-2919486

(State or other jurisdiction

of incorporation)

   (Commission
File Number)		  

(IRS Employer

Identification No.)

 

Waterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

 

(855) 776-6419

Registrant’s telephone number, including area code

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On August 20, 2026, the Company held its 2026 annual meeting of stockholders (the “2026 Annual Meeting”). The following proposals were voted on and approved by the Company’s stockholders at the 2026 Annual Meeting with the stockholders having voted as set forth below.

 

I.Proposal to approve Amended and Restated Certificate of Incorporation.

 

For   Against   Abstain   Broker Non-Vote 
 24,981,181    246,552    3,625    1,347,136 

 

II.Proposal to grant the Board of Directors of the Company (the “Board”) discretionary authority to amend the Certificate of Incorporation to effect a reverse stock split of Common Stock at a ratio in the range from one-for-two to one-for ten with the exact ratio, if any, to be determined by the Board, but not later than one year after stockholder approval thereof.

 

For   Against   Abstain   Broker Non-Vote 
 26,180,980    397,262    252    0 

 

III.Proposal to approve the Company’s 2026 Equity Incentive Plan.

 

For   Against   Abstain   Broker Non-Vote 
 24,887,762    339,193    4,403    1,347,136 

 

IV.Proposal to approve the Company’s 2026 Employee Stock Purchase Plan.

 

For   Against   Abstain   Broker Non-Vote 
 24,580,773    648,533    2,052    1,347,136 

 

V.Proposal to elect five director nominees who will serve until the 2027 annual meeting or until their successors are duly elected and qualified.

 

Name  For   Against   Withheld   Broker Non-Vote 
                 
Vijay Aggarwal   25,093,904    0    137,454    1,347,136 
Thomas W. Burnell   25,095,783    0    135,575    1,347,136 
Joseph D. Keegan, Ph.D.   24,422,783    0    808,575    1,347,136 
Fortunato Ron Rocca   24,422,706    0    808,652    1,347,136 
Stephen J. Sullivan   24,422,713    0    808,645    1,347,136 

 

VI.Proposal to approve a non-binding advisory vote on a resolution approving the compensation of our named executive officers.

 

For   Against   Abstain   Broker Non-Vote 
 24,952,970    249,460    28,928    1,347,136 

 

VII.Proposal to ratify the appointment of EisnerAmper, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2026.

 

For   Against   Abstain   Broker Non-Vote 
 26,442,760    134,660    1,074    0 

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interpace Biosciences, Inc.
     
  By /s/ Thomas W. Burnell
  Name: Thomas W. Burnell
  Title: President and Chief Executive Officer

 

Date August 20, 2026

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents